Comparison of maximum drug concentration and area under the time-concentration curve between humans and animals for oral and intravenous investigational drugs

Journal of Clinical Pharmacology

Volumn 46, Issue 6, 2006, Pages 674-692

  Fujita, Tomoe ^a,b,d   Matsumoto, Yoshiaki ^c,d   Ozaki, Machiko ^b,d   Majima, Masataka ^a,d   Kumagai, Yuji ^a,b,d   Ohtani, Yoshio ^b,d  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

^c NIHON UNIVERSITY   (Japan)

^d KITASATO UNIVERSITY   (Japan)

Author keywords

Area under the time concentration curve (AUC); Body surface area normalization; Linear regression analysis; Maximum drug concentration (C max); Phase I study

Indexed keywords

ANALGESIC AGENT; ANTIALLERGIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTIPARKINSON AGENT; ANTIRHEUMATIC AGENT; ANTIULCER AGENT; ANXIOLYTIC AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; GASTROINTESTINAL AGENT; HYPNOTIC SEDATIVE AGENT; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PROKINETIC AGENT; PSYCHOSTIMULANT AGENT; URINARY TRACT AGENT;

AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BODY WEIGHT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; NONHUMAN;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BODY SURFACE AREA; BODY WEIGHT; CLINICAL TRIALS, PHASE I; DRUGS, INVESTIGATIONAL; HUMANS; INJECTIONS, INTRAVENOUS; LINEAR MODELS;

EID: 33745262315     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006287932     Document Type: Article

References (17)

1. Boxenbaum H, DiLea C. First-time-in-human dose selection: allometric thoughts and perspectives. J Clin Pharmacol. 1995;35:957-966.
2. Thomas M. Study design and assessment of wanted and unwanted drug effects in phase I/II trials. In: O'Grady J, Joubert PH, eds. Handbook of Phase I/II Clinical Drug Trials. Boca Raton, Fla: CRC Press; 1997.
3. Nakashima M. Iyakuhin kaihatsu to rinshoshiken. In: Nakano S, Yasuhara H, Nakano M, eds. Rinshou Yakuri Gaku.Tokyo, Japan: Igaku-Shoind; 2003.
4. Food and Drug Administration. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Available at: http://www.fda.gov/cder/guidance/5541fnl.pdf.
5. Ozaki M, Fujita T, Yokota S, et al. A retrospective study on determining starting doses [in Japanese]. Jpn J Clin Pharmacol Ther. 2006;37, in press.
6. Chappell WR, Mordenti J. Extrapolation of toxicological and pharmacological data from animals to humans. Adv Drug Res. 1991;20:1-116.
7. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50:219-244.
8. Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci. 1986;75:1028-1040.
9. Collins JM, Zaharko DS, Dedrick RL, Chabner BA. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep. 1986;70:73-80.
10. Schwartz S. Toxicokinetics. In: Evans G, ed. A Handbook of Bioanalysis and Drug Metabolism. Boca Raton, Fla: CRC Press; 2004.
11. Fujimoto S, Watanabe T. Studies on the body surface area of Japanese. Acta Med Nagasaki. 1969;14:1-13.
12. Mahmood I, Balian JD. Interspecies scaling: predicting clearance of drugs in humans: three different approaches. Xenobiotica. 1996;26:887-895.
13. Travis CC, White RK. Interspecific scaling of toxicity data. Risk Anal. 1988;8:119-125.
14. Tingle MD, Mahmud R, Maggs JL, Pirmohamed M, Park BK. Comparison of the metabolism and toxicity of dapsone in rat, mouse and man. J Pharmacol Exp Ther. 1997;283:817-823.
15. Ammerschlaeger M, Beigel J, Klein KU, Mueller SO. Characterization of the species-specificity of peroxisome proliferators in rat and human hepatocytes. Toxicol Sci. 2004;78:229-240.
16. Khan KN, Venturini CM, Bunch RT, et al. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal anti-inflammatory drug-related nephrotoxicity. Toxicol Pathol. 1998;26:612-620.
17. Garattini S. Toxic effects of chemicals: difficulties in extrapolating data from animals to man. Crit Rev Toxicol. 1985;16:1-29.